Phase II open-label study of volociximab (M200) in combination with erlotinib hydrochloride (Tarceva) in previously treated patients with locally advanced (stage IIIb) or metastatic (stage IV) non-small cell lung cancer

Trial Profile

Phase II open-label study of volociximab (M200) in combination with erlotinib hydrochloride (Tarceva) in previously treated patients with locally advanced (stage IIIb) or metastatic (stage IV) non-small cell lung cancer

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 18 Dec 2013

At a glance

  • Drugs Erlotinib; Volociximab
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 30 Nov 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top